Mrna Therapeutics Contract Development Manufacturing Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The mRNA therapeutics CDMO market encompasses contract services spanning process development, scale-up manufacturing, analytical testing, and regulatory support for mRNA-based drug products. The market was valued at approximately $4.85 billion in 2024 and is on a rapid growth trajectory, with the 2026 addressable market estimated at roughly $10.2 billion, nearly doubling in two years. This segment sits within the broader mRNA therapeutics market, which is forecast to reach approximately $21.4 billion by 2032 at a 20% compound annual growth rate, underpinning sustained demand for CDMO services.

• •The broader global mRNA therapeutics market is projected to reach approximately $21.4 billion by 2032, growing at a 20% CAGR, serving as the primary demand driver for CDMO services.
• •The CDMO-specific market expanded from earlier estimates to roughly $4.85 billion in 2024, with projections pointing to approximately $10.2 billion by 2026 and further growth to around $14.63 billion by 2035.

The accelerating demand for CDMO services is rooted in the expanding pipeline of mRNA-based therapeutics across prophylactic vaccines, oncology, and rare genetic diseases, which requires specialized manufacturing infrastructure. The technical complexity of mRNA production, encompassing lipid nanoparticle formulation, cold-chain logistics, and precise quality control, creates high barriers to in-house manufacturing for many biopharmaceutical sponsors. Additionally, the capital-efficient CDMO model allows pharmaceutical companies to de-risk development programs by leveraging external expertise without committing to expensive internal manufacturing buildout.

• •The proliferation of mRNA vaccine candidates beyond COVID-19, including infectious disease and oncology applications, is generating sustained demand for scalable manufacturing capacity.
• •Metabolic and genetic diseases represent a growing therapeutic indication area within mRNA therapeutics, requiring specialized CDMO capabilities for personalized or niche product formats.

The market is segmented primarily by indication, including infectious diseases, metabolic and genetic diseases, and oncology, and by application, spanning viral vaccines, protein replacement therapies, and cancer immunotherapies. Prophylactic vaccines, encompassing both COVID-19 and non-COVID-19 vaccines, constitute a major application category alongside drugs and medications. Geographically, North America holds the largest share of CDMO capacity, supported by a dense biopharmaceutical R&D ecosystem, while Asia-Pacific is emerging as a competitive manufacturing hub driven by cost advantages and growing domestic biotech investment.

• •By indication, infectious diseases and oncology are the dominant segments, with metabolic and genetic diseases representing a fast-growing niche within the mRNA therapeutics portfolio.
• •North America commands the largest regional share of CDMO services, though Asia-Pacific is expanding its manufacturing footprint and gaining market share in the CDMO supply chain.

Who are the notable companies in the industry?

The global mRNA therapeutics Contract Development & Manufacturing Organization (CDMO) market is shaped by specialized players offering end-to-end services in mRNA synthesis, formulation, and regulatory support. ResearchAndMarkets.com identifies key participants whose positioning is defined by technical focus and service scope: Lonza specializes in end-to-end mRNA manufacturing with proprietary lipid nanoparticle (LNP) platforms; Catalent provides integrated development and commercial-scale production for viral vaccines and oncology indications; Thermo Fisher Scientific offers end-to-end solutions spanning plasmid DNA to final drug product, leveraging its global GMP network; Evotec focuses on early-phase development and process optimization for novel mRNA constructs; and BioNTech SE, while primarily a sponsor, operates an in-house CDMO-like infrastructure supporting its infectious disease and cancer pipelines. These firms dominate through technological differentiation in in vitro transcription, purification, and LNP delivery systems. North America leads in market share, driven by biotech outsourcing and regulatory maturity, while Asia-Pacific emerges as the fastest-growing region, with new entrants scaling GMP capacity. The market’s evolution is anchored in rising demand from biotech firms (63% share in 2024) and expanding pipelines in infectious diseases and genetic disorders, reinforcing the strategic role of CDMOs as enablers of mRNA innovation.

• •The competitive landscape features a mix of broad-spectrum large-scale CDMOs and smaller specialty providers focused on advanced therapy modalities, with consolidation activity reflecting the industry's capital intensity.
• •Regional capacity is concentrated in North America and Europe, though Asia-Pacific hosts rapidly expanding mRNA manufacturing facilities, creating a multi-hub global supply chain structure.
• •Technology and process routes, spanning IVT-based mRNA production, lipid nanoparticle encapsulation, and continuous manufacturing platforms, are the primary differentiating factors among CDMO competitors.

What are the recent trends and outlook?

The market's 20% annual growth rate is expected to sustain through the early 2030s, supported by the ongoing transition of mRNA technology from vaccines to therapeutic applications in oncology and genetic diseases. Investment in manufacturing flexibility, enabling rapid scale-up and multi-product facility use, is becoming a key competitive priority as sponsors seek CDMOs capable of supporting diverse pipeline portfolios. Regulatory harmonization and the development of standardized quality frameworks for mRNA products are anticipated to reduce development timelines and broaden the addressable market for CDMO services globally.

• •The shift from prophylactic vaccines toward therapeutic applications, including protein replacement therapies and cancer immunotherapies, is expected to diversify and expand CDMO demand over the forecast period.
• •Continued capacity expansion in Asia-Pacific and technological advancements in mRNA manufacturing processes are likely to intensify competitive dynamics and potentially moderate pricing pressure through 2035.